Delving into the Latest Updates on Voluloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [1]

Target

ENaC

Action

blockers

Mechanism

ENaC blockers(Epithelial sodium channel blockers)

Therapeutic Areas

Eye Diseases

Active Indication

Xerophthalmia

Inactive Indication-

Originator Organization

Parion Sciences, Inc.

Active Organization

Parion Sciences, Inc.Shire Pharmaceuticals Services Ltd.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC38H67ClN18O4

InChIKeyOKBDJMKISGUWNG-VSGBNLITSA-N

CAS Registry1498299-91-4

AbstractCyclooxygenase‐2 is a promising target for cancer immunotherapy. Here, we designed the analogues p321‐9L and p321‐1Y9L (YLIGETIKL) from cyclooxygenase‐2‐derived native peptide p321. Then, we tested the binding affinity and stability of the analogues and their ability to elicit specific immune response both in vitro (from PBMCs of HLA‐A*02+ healthy donors) and in vivo (from HLA‐A2.1/Kb transgenic mice). Our results indicated that the activity of cytotoxic T lymphocytes induced by p321‐9L and p321‐1Y9L was more potent than that of p321. In conclusion, the epitope analogue, especially p321‐1Y9L, may be a good candidate which could be used to the immunotherapy of patients with tumours expressing cyclooxygenase‐2.

100 Deals associated with Voluloride

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Phase 2	United States	Parion Sciences, Inc.	01 Jul 2016
Xerophthalmia	Phase 2	-	Shire Pharmaceuticals Services Ltd.	-
Xerophthalmia	Phase 2	-	Parion Sciences, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02831387 (CTgov)	Phase 2	Dry Eye Syndromes	47	P-321 Ophthalmic Solution	rpablebsfm(pneaxfrtol) = btxrjyrhxc mcazsffjoe (ybvuwsumcd, hhtupqcsxo - pkqljuhovl) View more	-	11 Oct 2018
NCT02824913 (CTgov)	Phase 2	Dry Eye Syndromes	1	P-321 Ophthalmic Solution (P-321 Ophthalmic Solution)	mfndcjwsqf(sfrjpygvkj) = cjitvsdfae mwbprbfsui (qccszspsnc, pwzlcrvyis - tlzkibpuuc) View more	-	19 Jan 2018
NCT02824913 (CTgov)	Phase 2	Dry Eye Syndromes	1	P-321 Ophthalmic Solution placebo (Drug: P-321 Ophthalmic Solution Placebo)	mfndcjwsqf(sfrjpygvkj) = dwqlbghdlv mwbprbfsui (qccszspsnc, cdzhlewqdu - kequvkbadc) View more	-	19 Jan 2018
ARVO2014	Not Applicable	-	-	P-321 0.1%	(axgftqwnbd) = increased slightly during multiple dose administration reaching steady state levels by Day 4 hqsbszqeiy (reoeygvqvo ) View more	-	01 Apr 2014